| P50 | author | Truong Tien Dang | Q89808764 |
| | Dinh-Toi Chu | Q41647914 |
| P2093 | author name string | Jee-Heon Jeong | |
| | Tiep Tien Nguyen | |
| | Nguyen Le Bao Tien | |
| | Vo Van Thanh | |
| | Thien Chu Dinh | |
| | Dang-Khoa Tran | |
| | Pham Gia Anh | |
| P2860 | cites work | Prospective identification of tumorigenic breast cancer cells | Q24683474 |
| | Neural Stem Cell Carriers for the Treatment of Glioblastoma Multiforme | Q26783167 |
| | The roles of mesenchymal stem cells in tumor inflammatory microenvironment | Q26823759 |
| | Human embryonic stem cells--a potential vaccine for ovarian cancer. | Q50927794 |
| | Deepening a Simple Question: Can MSCs Be Used to Treat Cancer? | Q51795939 |
| | CAR T-cell Therapy: a New Era in Cancer Immunotherapy. | Q52581187 |
| | Progress and challenges towards targeted delivery of cancer therapeutics. | Q52590993 |
| | Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation. | Q52602401 |
| | Long-term cultures of bone marrow-derived human mesenchymal stem cells frequently undergo spontaneous malignant transformation. | Q53390457 |
| | Oncolytic Viral Therapy and the Immune System: A Double-Edged Sword Against Cancer. | Q54213228 |
| | Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs. | Q54242542 |
| | The extracellular nucleotide UTP is a potent inducer of hematopoietic stem cell migration | Q56996006 |
| | Mesenchymal stem cells in preclinical cancer cytotherapy: a systematic review | Q59790772 |
| | Toward the development of true "off-the-shelf" synthetic T-cell immunotherapy | Q60922522 |
| | Cancer stem cell impact on clinical oncology | Q60934336 |
| | Mesenchymal stem cell exosomes: a two-edged sword in cancer therapy | Q64097130 |
| | Bone marrow-derived mesenchymal stem cells as vehicles for interferon-beta delivery into tumors | Q64378688 |
| | Adult Stem Cell Functioning in the Tumor Micro-Environment. | Q64941271 |
| | Improving Payload Capacity and Anti-Tumor Efficacy of Mesenchymal Stem Cells Using TAT Peptide Functionalized Polymeric Nanoparticles. | Q64991848 |
| | Cancer stem cells | Q80312237 |
| | Allogeneic marrow stromal cells are immune rejected by MHC class I- and class II-mismatched recipient mice | Q81104784 |
| | Sphingosine-1-phosphate facilitates trafficking of hematopoietic stem cells and their mobilization by CXCR4 antagonists in mice | Q82321708 |
| | Administration of embryonic stem cells generates effective antitumor immunity in mice with minor and heavy tumor load | Q84654667 |
| | Efficacy of bone marrow-derived mesenchymal stem cells in the treatment of sclerodermatous chronic graft-versus-host disease: clinical report | Q84931084 |
| | Nano-Engineered Mesenchymal Stem Cells Increase Therapeutic Efficacy of Anticancer Drug Through True Active Tumor Targeting | Q88204108 |
| | The Balancing Act between Cancer Immunity and Autoimmunity in Response to Immunotherapy | Q90226749 |
| | Conjugation of haematopoietic stem cells and platelets decorated with anti-PD-1 antibodies augments anti-leukaemia efficacy | Q90253675 |
| | Human iPSC-Derived Natural Killer Cells Engineered with Chimeric Antigen Receptors Enhance Anti-tumor Activity | Q90783045 |
| | Efficient lung cancer-targeted drug delivery via a nanoparticle/MSC system | Q91603938 |
| | Engineered Mesenchymal Stem Cell/Nanomedicine Spheroid as an Active Drug Delivery Platform for Combinational Glioblastoma Therapy | Q91660075 |
| | Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells: Results from the phase 1/2 TREAT-ME-1 trial | Q91884233 |
| | Induced Pluripotent Stem Cell-Based Cancer Vaccines | Q92136031 |
| | Mesenchymal Stem Cells and Cancer: Clinical Challenges and Opportunities | Q92798740 |
| | Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu | Q39679811 |
| | Human mesenchymal stem cells (hMSCs) target osteosarcoma and promote its growth and pulmonary metastasis. | Q39864787 |
| | High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability. | Q39953729 |
| | Cytosine deaminase expressing human mesenchymal stem cells mediated tumour regression in melanoma bearing mice. | Q39955301 |
| | Bone marrow-derived mesenchymal stem cells (JR-031) for steroid-refractory grade III or IV acute graft-versus-host disease: a phase II/III study | Q40273820 |
| | Induction of T-cell development from human cord blood hematopoietic stem cells by Delta-like 1 in vitro | Q40502047 |
| | Exosomes from marrow stromal cells expressing miR-146b inhibit glioma growth | Q41114486 |
| | Irradiation strongly reduces tumorigenesis of human induced pluripotent stem cells | Q41510841 |
| | Stem cells loaded with multimechanistic oncolytic herpes simplex virus variants for brain tumor therapy. | Q42218017 |
| | Studies on drug resistance in a human melanoma xenograft system | Q42667126 |
| | Allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies after dose-escalated treosulfan/fludarabine conditioning. | Q43055330 |
| | The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase. | Q43061941 |
| | Treatment of advanced gastrointestinal cancer with genetically modified autologous mesenchymal stem cells - TREAT-ME-1 - a phase I, first in human, first in class trial | Q43063875 |
| | Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning | Q43181730 |
| | Chemical engineering of mesenchymal stem cells to induce a cell rolling response | Q46273539 |
| | Chronic graft-versus-host disease following umbilical cord blood transplantation: retrospective survey involving 1072 patients in Japan | Q46535590 |
| | Concise Review: Cancer Cells, Cancer Stem Cells, and Mesenchymal Stem Cells: Influence in Cancer Development. | Q47104412 |
| | Anti-Donor Immune Responses Elicited by Allogeneic Mesenchymal Stem Cells and Their Extracellular Vesicles: Are We Still Learning? | Q47147635 |
| | Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf. | Q47215994 |
| | Chemically Edited Exosomes with Dual Ligand Purified by Microfluidic Device for Active Targeted Drug Delivery to Tumor Cells | Q47859833 |
| | Cancer stem cells as targets for immunotherapy | Q48278683 |
| | Generation of T cells from human embryonic stem cell-derived hematopoietic zones | Q49134707 |
| | Cancer stem cells revisited | Q49557760 |
| | Autologous iPSC-Based Vaccines Elicit Anti-tumor Responses In Vivo | Q49886571 |
| | Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors | Q27860937 |
| | Genetically modified mesenchymal stromal cells in cancer therapy | Q28071840 |
| | Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing | Q28131793 |
| | Regulation of inflammation by extracellular acidification and proton-sensing GPCRs | Q28296062 |
| | Cancer statistics, 2016 | Q29547383 |
| | Mesenchymal stem cells within tumour stroma promote breast cancer metastasis | Q29614303 |
| | Mesenchymal and haematopoietic stem cells form a unique bone marrow niche | Q29616602 |
| | Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study | Q29617267 |
| | Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment | Q29620053 |
| | Intravenous hMSCs improve myocardial infarction in mice because cells embolized in lung are activated to secrete the anti-inflammatory protein TSG-6 | Q29620590 |
| | Life expectancy in patients surviving more than 5 years after hematopoietic cell transplantation | Q33710708 |
| | Novel trafficking routes for hematopoietic stem and progenitor cells | Q33763039 |
| | Therapeutic cell engineering with surface-conjugated synthetic nanoparticles | Q34112602 |
| | Direct evidence of mesenchymal stem cell tropism for tumor and wounding microenvironments using in vivo bioluminescent imaging | Q34162598 |
| | Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by bioluminescence imaging | Q34164696 |
| | TNFα and IL-1β influence the differentiation and migration of murine MSCs independently of the NF-κB pathway | Q34255259 |
| | Viral and nonviral delivery systems for gene delivery | Q34315475 |
| | How do stem cells find their way home? | Q34418463 |
| | Stem cell engraftment at the endosteal niche is specified by the calcium-sensing receptor | Q34480347 |
| | Tackling the cancer stem cells - what challenges do they pose? | Q34523263 |
| | Systemically delivered measles virus-infected mesenchymal stem cells can evade host immunity to inhibit liver cancer growth. | Q35073868 |
| | Enhancing Cell therapies from the Outside In: Cell Surface Engineering Using Synthetic Nanomaterials | Q35142623 |
| | Co-treatment with therapeutic neural stem cells expressing carboxyl esterase and CPT-11 inhibit growth of primary and metastatic lung cancers in mice | Q35149583 |
| | Long-term complications and side effects after allogeneic hematopoietic stem cell transplantation: an update | Q35664284 |
| | Donor-derived mesenchymal stem cells are immunogenic in an allogeneic host and stimulate donor graft rejection in a nonmyeloablative setting | Q35849125 |
| | Mobilization and collection of peripheral blood progenitor cells for transplantation | Q36057871 |
| | Neural Stem Cells Secreting Anti-HER2 Antibody Improve Survival in a Preclinical Model of HER2 Overexpressing Breast Cancer Brain Metastases. | Q36083446 |
| | The role of sphingosine 1-phosphate receptors in the trafficking of hematopoietic progenitor cells | Q36164489 |
| | Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma | Q36232448 |
| | Hematopoietic stem-cell transplantation | Q36461248 |
| | Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer | Q36597119 |
| | Encapsulated therapeutic stem cells implanted in the tumor resection cavity induce cell death in gliomas | Q36695971 |
| | Recruitment of mesenchymal stem cells into prostate tumours promotes metastasis | Q36831102 |
| | Synergistic effect of therapeutic stem cells expressing cytosine deaminase and interferon-beta via apoptotic pathway in the metastatic mouse model of breast cancer | Q36905824 |
| | Immunomodulation by mesenchymal stem cells and clinical experience | Q36975987 |
| | The timing of neural stem cell-based virotherapy is critical for optimal therapeutic efficacy when applied with radiation and chemotherapy for the treatment of glioblastoma | Q37124552 |
| | Immunogenicity of allogeneic mesenchymal stem cells. | Q37294916 |
| | Tumor-specific gene therapy for pancreatic cancer using human neural stem cells encoding carboxylesterase | Q37688944 |
| | Bone marrow mesenchymal stromal cells to treat tissue damage in allogeneic stem cell transplant recipients: correlation of biological markers with clinical responses. | Q37710227 |
| | Optimization of a Neural Stem-Cell-Mediated Carboxylesterase/Irinotecan Gene Therapy for Metastatic Neuroblastoma | Q37718554 |
| | Cancer stem cells and self-renewal. | Q37763416 |
| | The suppressive tumor microenvironment: a challenge in cancer immunotherapy | Q37872288 |
| | Therapeutic factors secreted by mesenchymal stromal cells and tissue repair | Q37900258 |
| | Combining immunotherapy and targeted therapies in cancer treatment | Q37995939 |
| | Anti-donor immune responses elicited by allogeneic mesenchymal stem cells: what have we learned so far? | Q38064659 |
| | A role for cancer stem cells in therapy resistance: cellular and molecular mechanisms | Q38222546 |
| | Cellular uptake of nanoparticles: journey inside the cell. | Q38557482 |
| | Drug Loaded Gingival Mesenchymal Stromal Cells (GinPa-MSCs) Inhibit In Vitro Proliferation of Oral Squamous Cell Carcinoma | Q38637527 |
| | Paclitaxel-releasing mesenchymal stromal cells inhibit the growth of multiple myeloma cells in a dynamic 3D culture system. | Q38765403 |
| | PLK-1 Silencing in Bladder Cancer by siRNA Delivered With Exosomes | Q38794196 |
| | Fail-Safe Therapy by Gamma-Ray Irradiation Against Tumor Formation by Human-Induced Pluripotent Stem Cell-Derived Neural Progenitors | Q38883920 |
| | Modulation of tissue tropism and biological activity of exosomes and other extracellular vesicles: New nanotools for cancer treatment. | Q38890934 |
| | Active loading into extracellular vesicles significantly improves the cellular uptake and photodynamic effect of porphyrins | Q38931316 |
| | Cancer stem cells: Role in tumor growth, recurrence, metastasis, and treatment resistance | Q38950219 |
| | Cancer stem cell signaling pathways | Q38950221 |
| | Surface functionalization of exosomes using click chemistry | Q38956657 |
| | Paclitaxel is incorporated by mesenchymal stromal cells and released in exosomes that inhibit in vitro tumor growth: a new approach for drug delivery | Q38969541 |
| | Enzyme/Prodrug Systems for Cancer Gene Therapy. | Q39064497 |
| | Selective antitumor effect of neural stem cells expressing cytosine deaminase and interferon-beta against ductal breast cancer cells in cellular and xenograft models | Q39076523 |
| | Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy. | Q39177978 |
| | Adipose tissue-derived mesenchymal stromal cells as part of therapy for chronic graft-versus-host disease: A phase I/II study | Q39190802 |
| | Cytosine deaminase-expressing human neural stem cells inhibit tumor growth in prostate cancer-bearing mice | Q39197985 |
| | Mesenchymal stromal cells primed with Paclitaxel attract and kill leukaemia cells, inhibit angiogenesis and improve survival of leukaemia-bearing mice | Q39215411 |
| | NF-κB activity regulates mesenchymal stem cell accumulation at tumor sites | Q39259185 |
| | Bone marrow-derived mesenchymal stromal cells are attracted by multiple myeloma cell-produced chemokine CCL25 and favor myeloma cell growth in vitro and in vivo | Q39439676 |
| | Both human and mouse mesenchymal stem cells promote breast cancer metastasis. | Q39505707 |
| | Nanoparticulate cellular patches for cell-mediated tumoritropic delivery | Q39564643 |
| | Mesenchymal stem cells as cellular vehicles for delivery of nanoparticles to brain tumors. | Q39670726 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P577 | publication date | 2020-02-28 | |
| P1433 | published in | Cells | Q27724621 |
| P1476 | title | Recent Progress of Stem Cell Therapy in Cancer Treatment: Molecular Mechanisms and Potential Applications | |
| P478 | volume | 9 | |